This previously developed ‘Leukemia-on-a-Chip’ model recapitulated in vivo leukemic bone marrow niche, which allowed for a preclinical evaluation of chemotherapy45 and CD19 CAR T cell therapy46, 47 (Fig. 2e). This evidence concerns the gene CD19 and leukemia.